Ruxolitinib in COVID-19 patients with defined hyperinflammation: the RuxCoFlam trial

被引：0

作者：

Birndt, S. ^{[1
]}

Hammersen, J. ^{[1
]}

Doehner, K. ^{[2
]}

Reuken, P. ^{[3
]}

Sauerbrey, P. ^{[1
]}

La Rosee, F. ^{[4
]}

Pfirrmann, M. ^{[5
]}

Fabisch, C. ^{[1
]}

Weiss, M. ^{[6
]}

Traeger, K. ^{[6
]}

Bremer, H. ^{[7
]}

Illerhaus, G. ^{[8
]}

Droemann, D. ^{[9
]}

Schneider, S. ^{[10
]}

La Rosee, P. ^{[11
]}

Hochhaus, A. ^{[1
]}

机构：

[1] Univ Klinikum Jena, Klin Innere Med Hamatol & Internist Onkol 2, Jena, Germany

[2] Univ Klinikum Ulm, Klin Innere Med 3, Ulm, Germany

[3] Univ Klinikum Jena, Klin Innere Med 4, Interdisziplinare Endoskopie, Hepatol,Infektiol,Gastroenterol, Jena, Germany

[4] Univ Klinikum Dresden, Med Fak, Dresden, Germany

[5] LMU Munchen, Inst Med Informat Verarbeitung Biometrie & Epidem, Med Fak, Munich, Germany

[6] Univ Klinikum Ulm, Klin Anasthesiol & Intens Med, Ulm, Germany

[7] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Donaueschingen, Germany

[8] Klinikum Stuttgart, Klin Hamatol Onkol Stammzellentransplantat & Pall, Stuttgart, Germany

[9] Univ Klinikum Schleswig Holstein, Med Klin Pulmol 3, Campus Lubeck, Lubeck, Germany

[10] SRH Klinikum Gera, Gera, Germany

[11] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infektiol &, Villingen Schwenningen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V497

引用

页码：71 / 71

页数：1

共 50 条

[1] Ruxolitinib in COVID-19 patients with defined hyperinflammation: The RuxCoFlam trial
Hammersen, J.
Birndt, S.
Doehner, K.
Fabisch, C.
Weiss, M.
Bremer, H.
Illerhaus, G.
Droemann, D.
La Rosee, P.
Hochhaus, A.
MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2023, 118 (05)
[2] The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Hammersen, J.
Birndt, S.
Doehner, K.
Reuken, P.
Stallmach, A.
Sauerbrey, P.
La Rosee, F.
Pfirrmann, M.
Fabisch, C.
Weiss, M.
Traeger, K.
Bremer, H.
Russo, S.
Illerhaus, G.
Droemann, D.
Schneider, S.
La Rosee, P.
Hochhaus, A.
LEUKEMIA, 2023, 37 (9) : 1879 - 1886
[3] The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
J. Hammersen
S. Birndt
K. Döhner
P. Reuken
A. Stallmach
P. Sauerbrey
F. La Rosée
M. Pfirrmann
C. Fabisch
M. Weiss
K. Träger
H. Bremer
S. Russo
G. Illerhaus
D. Drömann
S. Schneider
P. La Rosée
A. Hochhaus
Leukemia, 2023, 37 : 1879 - 1886
[4] Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies
La Rosee, Felicitas
La Rosee, Paul
ACTA HAEMATOLOGICA, 2021, 144 (03) : 246 - 248
[5] Management of hyperinflammation in COVID-19 patients
Suberviola, Borja
Cuenca Fito, Elena
REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 6 - 9
[6] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
F. La Rosée
H. C. Bremer
I. Gehrke
A. Kehr
A. Hochhaus
S. Birndt
M. Fellhauer
M. Henkes
B. Kumle
S. G. Russo
P. La Rosée
Leukemia, 2020, 34 : 1805 - 1815
[7] The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
La Rosee, F.
Bremer, H. -C.
Hochhaus, A.
Birndt, S.
Fellhauer, M.
Henkes, M.
Russo, S. G.
La Rosee, P.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 198 - 198
[8] The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
La Rosee, F.
Bremer, H. C.
Gehrke, I
Kehr, A.
Hochhaus, A.
Birndt, S.
Fellhauer, M.
Henkes, M.
Kumle, B.
Russo, S. G.
La Rosee, P.
LEUKEMIA, 2020, 34 (07) : 1805 - 1815
[9] Immunopathology of Hyperinflammation in COVID-19
Gustine, Joshua N.
Jones, Dennis
AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (01): : 4 - 17
[10] Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
Sarmiento, Mauricio
Rojas, Patricio
Jerez, Joaquin
Bertin, Pablo
Campbell, James
Garcia, Maria J.
Pereira, Jaime
Triantafilo, Nicolas
Ocqueteau, Mauricio
ACTA HAEMATOLOGICA, 2021, 144 (06) : 620 - 626

← 1 2 3 4 5 →